Hepatitis C Therapies Market Set To Grow To $20.7 Bn By 2021

08 August 2018
Pharma

Visiongain’ has launched a new Pharmaceutical Report Hepatitis C Therapies Market 2017-2027: Revenue Forecasts for Hepatitis C Therapeutics, Direct-Acting Antivirals, Ribavirin, Protease Inhibitors, Polymerase Inhibitors, Interferons & R&D.

The report forecasts the overall hepatitis C therapies market will multiply in revenues from 2017 to 2027. The pharmaceutical segment is evolving. Newly approved medications are achieving commercial success with some products gaining blockbuster status. Visiongain reports the strength of the HCV drugs market is its oral antiviral treatments enabling shorter treatment regimens and higher cure rates, reportedly with fewer side effects than the standard care – peginterferon and ribavirin. Steady growth is predicted for the hepatitis C market during the forecast period of this report. This is primarily due to the strong pipeline for antiviral treatments and increased awareness of Hepatitis C. Several drugs are expected to be approved during the forecast period.

The visiongain report analyst commented “The future of the hepatitis C market looks promising, as a number of new therapies are coming on to the market. Recent and expected forthcoming approvals of all-oral regimens, particularly interferon-free and also ribavirin-free, will stimulate growth of the market and feed the demand for more efficacious and convenient treatments. Although these regimens will come at a greater cost than the current standard of care – peginterferon and ribavirin – they have fewer side effects and are a welcome advance by patients and physicians alike.

In 2016, the greatest interest in the hepatitis C market was the development of protease and polymerase antivirals. Several companies have molecules in phase II and III trials, with at least 5 expected to gain approval within the first half of the forecast period. Although the overall world hepatitis C drugs market earned $19bn in 2016, we expect it to reach $20.7bn in 2021. The hepatitis C market is rapidly evolving and will contribute billions to the pharmaceutical market in the coming 10 years.”

The new report shows revenue forecasts to 2025 at overall world market, submarket, product and national level. It forecasts these world-level submarkets:

• Interferon treatments
• Oral antiviral therapy.

That investigation predicts revenues of eight leading products in the market, including Harvoni, Sovaldi, Epclusa, Daklinza,Zepatier, Sunverpa Pegasys,, PegIntron and Olysiol. Revenue forecasts are also included of Research, data and analyses covering activities of Gilead Sciences, Johnson & Johnson, Roche, Bristol-Myers Squibb, Merck & Co., AbbVie, Achillion Pharmaceuticals and other companies.

Analyses cover R&D and commercial news, show two research interviews and predict revenues to 2027 in leading regional markets. This includes the US, Japan, Germany, the UK, France, Italy, Spain (EU5 group), Brazil, Russia, India and China (BRIC countries).

Hepatitis C Therapies: World Industry, R&D and Market Forecasts 2017-2027 adds to visiongain’s range of reports on industries and markets in healthcare. Together these studies cover medical devices, diagnostics and pharmaceuticals.

Leading companies featured in the report who are developing Hepatitis C therapeutics include Gilead Sciences, Merck and Co., Bristol Myers Squibb, Roche, Janssen, Medivir, Abbvie, Achillion Pharmaceuticals.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever